Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

References

• Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010;341:c5475.
   PubMed Web of Science ®Google Scholar
• Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health 2015;36:559–574.
   PubMed Web of Science ®Google Scholar
• Adamson SJ, Deering DE, Sellman JD, Sheridan J, Henderson C, Robertson R, et al. An estimation of the prevalence of opioid dependence in New Zealand. Int J Drug Policy 2012;23:87–89.
   PubMed Web of Science ®Google Scholar
• Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in Drug and Opioid Overdose Deaths–United States, 2000–2014. MMWR Morb Mortal Wkly Rep 2016;64:1378–1382.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies–tackling the opioid-overdose epidemic. N Engl J Med 2014;370:2063–2066.
   PubMed Web of Science ®Google Scholar
• Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2008:CD004147.
   Google Scholar
• Popik P, Layer RT, Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol Rev 1995;47:235–253.
   PubMed Web of Science ®Google Scholar
• Fernandez JW, Fernandez RL. “Returning to the path”: the use of iboga[ine] in an equatorial African ritual context and the binding of time, space, and social relationships. Alkaloids Chem Biol 2001;56:235–247.
   PubMedGoogle Scholar
• Glue P, Lockhart M, Lam F, Hung N, Hung CT, Friedhoff L. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol 2015;55:189–194.
   PubMed Web of Science ®Google Scholar
• Lotsof HS, Alexander NE. Case studies of ibogaine treatment: implications for patient management strategies. Alkaloids Chem Biol 2001;56:293–313.
   PubMedGoogle Scholar
• Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am J Addict 1999;8:234–242.
   PubMed Web of Science ®Google Scholar
• Glue P, Winter H, Garbe K, Jakobi H, Lyudin A, Lenagh-Glue Z, et al. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. J Clin Pharmacol 2015;55:680–687.
   PubMed Web of Science ®Google Scholar
• Koenig X, Kovar M, Boehm S, Sandtner W, Hilber K. Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk. Addict Biol 2014;19:237–239.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011;106:32–51.
   PubMed Web of Science ®Google Scholar
• Brown TK. Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev 2013;6:3–16.
   PubMedGoogle Scholar
• Mash DC, Ameer B, Prou D, Howes JF, Maillet EL. Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. J Psychopharmacol 2016;30:688–697.
   PubMed Web of Science ®Google Scholar
• Medsafe. Minutes of the 42nd Meeting of the Medicines Classification Committee. Available from: http://www.medsafe.govt.nz/profs/class/mccmin03nov2009.htm [last accessed February 2016]. 2009 [cited 2016]; Minutes from NZ organizaiton meeting].
   Google Scholar
• McLellan T, Cacciola J, Carise D, Coyne TH. Addiction Severity Index Lite-CF. Clinical/Training Version 1999;Available from: Sept 2014 http://m.breining.edu/ASILite112909.pdf.
   Google Scholar
• McLellan AT, Luborsky L, Cacciola J, Griffith J, Evans F, Barr HL, et al. New data from the Addiction Severity Index. Reliability and validity in three centers. J Nerv Ment Dis 1985;173:412–423.
   PubMed Web of Science ®Google Scholar
• Beck AT, Steer RA, Brown GK. Manual for the beck depression inventory-II. San Antonio, TX: Psychological Corporation 1996;1:82.
   Google Scholar
• Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987;13:293–308.
   PubMed Web of Science ®Google Scholar
• Health and Disability Commissioner. A Report by the Health and Disability Commissioner. Available from: http://www.hdc.org.nz/media/289826/13hdc00966.pdf [last accessed 18 February 2016]. Coroner’s report: New Zealand Health and Disability Commissioner. 2015. Report No.: 13HDC00966.
   Google Scholar
• Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009;104:256–265.
   PubMed Web of Science ®Google Scholar
• Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol 2008;115:9–24.
   PubMed Web of Science ®Google Scholar
• Noller G, Henderson C. Report of the National Needle Exchange Blood-borne Virus Seroprevalence Survey. [BBVNEX2013] to the New Zealand Ministry of Health. Christchurch, New Zealand: National Office of the New Zealand Needle Exchange Programme; 2014.
   Google Scholar
• Winstock AR, Lintzeris N, Lea T. “Should I stay or should I go?” Coming off methadone and buprenorphine treatment. Int J Drug Policy 2011;22:77–81.
   PubMed Web of Science ®Google Scholar
• Mash DC, Kovera CA, Pablo J, Tyndale R, Ervin FR, Kamlet JD, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol 2001;56:155–171.
   PubMedGoogle Scholar
• Mathew RJ, Swihart AA, Weinman ML. Vegetative symptoms in anxiety and depression. Br J Psychiatry 1982;141:162–165.
   PubMed Web of Science ®Google Scholar
• Beck AT. Depression: Clinical, experimental, and theoretical aspects. Philadelphia, PA: University of Pennsylvania Press; 1967.
   Google Scholar
• Brown T. Results from the MAPS Mexico-based Ibogaine Study. 5th Global Ibogaine Conference; 2016 March 14–16; Tepoztlan, Mexico.
   Google Scholar
• Alper KR, Stajic M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci 2012;57:398–412.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquin-sparteine polymorphism. Clin Pharmacol Ther 1991;50:233–238.
   PubMed Web of Science ®Google Scholar
• Sheppard SG. A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat 1994;11:379–385.
   PubMed Web of Science ®Google Scholar
• Luciano D. Observations on treatment with ibogaine. Am J Addict 1998;7:89–90.
   PubMed Web of Science ®Google Scholar
• Mash DC, Kovera CA, Pablo J, Tyndale RF, Ervin FD, Williams IC, et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci 2000;914:394–401.
   PubMed Web of Science ®Google Scholar
• Bastiaans E. Life after ibogaine: an exploratory study of the long-term effects of ibogaine treatment on drug addicts. Doctorandus thesis Vrije Universiteit Amsterdam, Faculty of Medicine. Available from: https://www.iceers.org/docs/science/iboga/Bastiaans%20E_Life_After_Ibogaine.pdf [last accessed 2004].
   Google Scholar